GSK will pay $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. It will also make milestone ...

The volumes were tepid in January, but with flu, Covid-19 and other viral infections spreading fast, February and March saw spikes in volum...

Drugmaker Cipla said it is scaling up offerings and expanding access to medicines, inhaler devices, diagnostics, as it aspires to become th...

India’s benchmark indices are trading more than 30% off their record highs, as investors are concerned about the economic damage of the loc...

"The business has embarked on it new strategy this year, as we put in place an optimal commercial structure and worked at building capabili...

For one of the oldest multinational drug makers in the country, the growth curve has been challenging.

Five stocks to look at in the current market scenario marked by uncertainties.

The Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief to patients suffering from cystic...

"We've expanded foods where we can get the best returns, but as of now, it's in select markets. Foods business contributes close to 6% of o...

The Indian arm of British drugmaker GlaxoSmithKline (GSK) is planning a major initiative to wrestle back ground it had conceded.

Analysts at Emkay Global Financial Services are of the view that the launch will have a strong positive impact on the company’s margins.

"We are a debt-free company with cash in balance and can raise over a billion dollar-and-half," said CEO Vinita Gupta .

Glaxo will get Novartis’ vaccine portfolio, including anti-rabies products such as Rabipur, while transferring its smaller oncology busines...

"I think it is wholly reasonable for a country that is having a tremendous growth with challenges has to think about pricing," Witty said.

GlaxoSmithKline Pharmaceuticals today reported a 37.52 per cent rise in its net profit to Rs 169.01 crore for the first quarter ended March...

GlaxoSmithKline today reported 4.44 per cent rise in net profit at Rs 152.34 crore for the quarter ended September 30, 2012 on back of robu...

Cipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...